单位：[1]Department of Nuclear Medicine and Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Sciences (CAMS) and PUMC[2]Department of Nuclear Medicine, China-Japan Friendship Hospital[3]Respiratory Department, PUMC Hospital, CAMS and PUMC[4]Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing[5]PET-CT Center, General Hospital of Tianjin MedicalUniversity, Tianjin[6]Key Laboratory of Endocrinology of National Health and Family Planning Commission, PUMC Hospital, CAMS and PUMC, Beijing, People’s Republic of China.
Purpose This pilot study aimed to prove the complementary value of a novel (68)Gallium-labeled heterodimeric peptide, Ga-68-NOTA-3P-TATE-RGD, in detection and evaluation of tumors with somatostatin receptor subtype 2 or integrin alpha(v)beta(3) overexpression, including non-small cell lung cancer (NSCLC), small-cell lung cancer (SCLC), neuroendocrine tumor (NET), and neuroendocrine carcinoma (NEC). Methods With institute review board approval and written informed consent, 32 patients with pathologically diagnosed lung cancer (18 NSCLC, 14 SCLC) and 12 patients with neuroendocrine neoplasm (8 NET, 4 NEC) patients were recruited to undergo Ga-68-NOTA-3P-TATE-RGD PET/CT. For comparison, the NSCLC patients also underwent Ga-68-NOTA-TATE PET/CT, the SCLC patients underwent Ga-68-NOTA-RGD PET/CT, and the neuroendocrine neoplasm patients underwent F-18-FDG PET/CT within 3 days. The maximum standardized uptake value (SUV) of the primary tumor (T) and mean SUV of the blood pool (B) were measured, and the T/B ratios were calculated for comparison. Results In the primary tumors of NSCLC, the T/B ratios of Ga-68-NOTA-3P-TATE-RGD were significantly higher than those of Ga-68-NOTA-TATE (4.54 +/- 3.00 versus 4.10 +/- 2.83, P = 0.0058). In SCLC, the T/B ratios of Ga-68-NOTA-3P-TATE-RGD were significantly higher than those of Ga-68-NOTA-RGD (6.06 +/- 6.09 versus 2.65 +/- 1.19, P = 0.0344). In NET, the T/B ratios of Ga-68-NOTA-3P-TATE-RGD were 36.13 +/- 33.84, significantly higher than those of F-18-FDG (2.91 +/- 1.71, P = 0.0234). In NEC, there were no significant difference between the T/B ratios of Ga-68-NOTA-3P-TATE-RGD (4.80 +/- 0.85) and those of F-18-FDG (3.56 +/- 0.74, P = 0.1833). Conclusions This proof-of-concept study preliminarily demonstrates the efficacy of the dual targeting Ga-68-NOTA-3P-TATE-RGD PET/CT in the evaluation of lung cancer and neuroendocrine neoplasm in a single scan.
基金：
Key Special Project on Inter-Governmental Scientific and Technological Innovation Cooperation in National Key Research and Development Plan [2016YFE0115400]; Chinese Academy of Medical Science Major Collaborative Innovation Project [2016-I2M-1-011]; National Nature Science FoundationNational Natural Science Foundation of China (NSFC) [81741142, 81871392]; Beijing Municipal Natural Science FoundationBeijing Natural Science Foundation [7161012]
第一作者单位：[1]Department of Nuclear Medicine and Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Sciences (CAMS) and PUMC[2]Department of Nuclear Medicine, China-Japan Friendship Hospital
通讯作者：
通讯机构：[6]Key Laboratory of Endocrinology of National Health and Family Planning Commission, PUMC Hospital, CAMS and PUMC, Beijing, People’s Republic of China.[*1]Department of NuclearMedicine, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Sciences and PUMC, Beijing 100730, People’s Republic of China.
推荐引用方式(GB/T 7714)：
Zheng Yumin,Wang Hanping,Tan Huangying,et al.Evaluation of Lung Cancer and Neuroendocrine Neoplasm in a Single Scan by Targeting Both Somatostatin Receptor and Integrin alpha v beta 3[J].CLINICAL NUCLEAR MEDICINE.2019,44(9):687-694.doi:10.1097/RLU.0000000000002680.
APA：
Zheng, Yumin,Wang, Hanping,Tan, Huangying,Cui, Xiaoxia,Yao, Shaobo...&Zhu, Zhaohui.(2019).Evaluation of Lung Cancer and Neuroendocrine Neoplasm in a Single Scan by Targeting Both Somatostatin Receptor and Integrin alpha v beta 3.CLINICAL NUCLEAR MEDICINE,44,(9)
MLA：
Zheng, Yumin,et al."Evaluation of Lung Cancer and Neuroendocrine Neoplasm in a Single Scan by Targeting Both Somatostatin Receptor and Integrin alpha v beta 3".CLINICAL NUCLEAR MEDICINE 44..9(2019):687-694
